Linnea M Baudhuin

List of Publications by Year
in descending order

44 papers	1,646 citations	516710 16 h-index	315739 38 g-index
46 all docs	46 docs citations	46 times ranked	2942 citing authors

#	Article	IF	Citations
1	Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2020, 324, 761.	7.4	257
2	Preemptive Genotyping for Personalized Medicine: Design of the Right Drug, Right Dose, Right Timeâ€"Using Genomic Data to Individualize Treatment Protocol. Mayo Clinic Proceedings, 2014, 89, 25-33.	3.0	250
3	Preemptive Pharmacogenomic Testing for Precision Medicine. Journal of Molecular Diagnostics, 2016, 18, 438-445.	2.8	171
4	Clopidogrel Pharmacogenetics. Circulation: Cardiovascular Interventions, 2019, 12, e007811.	3.9	139
5	Use of Microsatellite Instability and Immunohistochemistry Testing for the Identification of Individuals at Risk for Lynch Syndrome. Familial Cancer, 2005, 4, 255-265.	1.9	109
6	Confirming Variants in Next-Generation Sequencing Panel Testing by Sanger Sequencing. Journal of Molecular Diagnostics, 2015, 17, 456-461.	2.8	109
7	Outcome of Whole Exome Sequencing for Diagnostic Odyssey Cases of an Individualized Medicine Clinic. Mayo Clinic Proceedings, 2016, 91, 297-307.	3.0	83
8	Increased frequency of FBN1 truncating and splicing variants in Marfan syndrome patients with aortic events. Genetics in Medicine, 2015, 17, 177-187.	2.4	71
9	Relation of ADRB1, CYP2D6, and UGT1A1 Polymorphisms With Dose of, and Response to, Carvedilol or Metoprolol Therapy in Patients With Chronic Heart Failure. American Journal of Cardiology, 2010, 106, 402-408.	1.6	51
10	Prevalence and Spectrum of Large Deletions or Duplications in the Major Long QT Syndrome-Susceptibility Genes and Implications for Long QT Syndrome Genetic Testing. American Journal of Cardiology, 2010, 106, 1124-1128.	1.6	51
11	UGT1A1 Genetic Analysis as a Diagnostic Aid for Individuals with Unconjugated Hyperbilirubinemia. Journal of Pediatrics, 2013, 162, 1146-1152.e2.	1.8	44
12	â€œBig Dataâ€•in Laboratory Medicine. Clinical Chemistry, 2015, 61, 1433-1440.	3.2	29
13	Analysis of hMLH1 and hMSH2 Gene Dosage Alterations in Hereditary Nonpolyposis Colorectal Cancer Patients by Novel Methods. Journal of Molecular Diagnostics, 2005, 7, 226-235.	2.8	28
14	Comparison of three methods for genotyping the UGT1A1 (TA)n repeat polymorphism. Clinical Biochemistry, 2007, 40, 710-717.	1.9	25
15	Technical Advances for the Clinical Genomic Evaluation of Sudden Cardiac Death. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	21
16	Electrophoretic measurement of lipoprotein(a) cholesterol in plasma with and without ultracentrifugation: comparison with an immunoturbidimetric lipoprotein(a) method. Clinical Biochemistry, 2004, 37, 481-488.	1.9	20
17	Decreased frequency of FBN1 missense variants in Ghent criteria-positive Marfan syndrome and characterization of novel FBN1 variants. Journal of Human Genetics, 2015, 60, 241-252.	2.3	18
18	How novel molecular diagnostic technologies and biomarkers are revolutionizing genetic testing and patient care. Expert Review of Molecular Diagnostics, 2012, 12, 25-37.	3.1	15

#	Article	IF	Citations
19	MYH Y165C and G382D mutations in hepatocellular carcinoma and cholangiocarcinoma patients. Journal of Cancer Research and Clinical Oncology, 2006, 132, 159-162.	2.5	14
20	The FDA and 23andMe: Violating the First Amendment or Protecting the Rights of Consumers?. Clinical Chemistry, 2014, 60, 835-837.	3.2	14
21	What Is the True Prevalence of Hypertrophic Cardiomyopathy?. Journal of the American College of Cardiology, 2015, 66, 1845-1846.	2.8	14
22	Genetics of coronary artery disease: focus on genome-wide association studies. American Journal of Translational Research (discontinued), 2009, 1, 221-34.	0.0	14
23	International survey of patients undergoing percutaneous coronary intervention and their attitudes toward pharmacogenetic testing. Pharmacogenetics and Genomics, 2019, 29, 76-83.	1.5	13
24	Genomics Integration Into Nephrology Practice. Kidney Medicine, 2021, 3, 785-798.	2.0	13
25	Variability in gene-based knowledge impacts variant classification: an analysis of FBN1 missense variants in ClinVar. European Journal of Human Genetics, 2019, 27, 1550-1560.	2.8	12
26	Variability in assigning pathogenicity to incidental findings: insights from LDLR sequence linked to the electronic health record in 1013 individuals. European Journal of Human Genetics, 2017, 25, 410-415.	2.8	10
27	Genetic variation in statin intolerance and a possible protective role for UGT1A1. Pharmacogenomics, 2018, 19, 83-94.	1.3	10
28	Clinical UGT1A1 Genetic Analysis in Pediatric Patients: Experience of a Reference Laboratory. Molecular Diagnosis and Therapy, 2017, 21, 327-335.	3.8	8
29	Miniaturized Nanopore DNA Sequencing: Accelerating the Path to Precision Medicine. Clinical Chemistry, 2017, 63, 632-634.	3.2	7
30	Predictive and Precision Medicine with Genomic Data. Clinical Chemistry, 2020, 66, 33-41.	3.2	7
31	Harmonizing the Collection of Clinical Data on Genetic Testing Requisition Forms to Enhance Variant Interpretation in Hypertrophic Cardiomyopathy (HCM). Journal of Molecular Diagnostics, 2021, 23, 589-598.	2.8	5
32	Genetic and biochemical analyses in dyslipidemic patients undergoing LDL apheresis. Journal of Clinical Apheresis, 2014, 29, 256-265.	1.3	4
33	Determining the Optimal Approach for Government-Regulated Genetic Testing. Clinical Chemistry, 2011, 57, 7-8.	3.2	3
34	Genetic considerations in the treatment of familial hypercholesterolemia. Clinical Lipidology, 2015, 10, 387-403.	0.4	2
35	Molecular Diagnostics: Going from Strength to Strength. Clinical Chemistry, 2020, 66, 1-2.	3.2	2
36	Consumer-initiated Genetic Testing and Pharmacogenomics. Advances in Molecular Pathology, 2019, 2, 133-142.	0.4	1

#	Article	IF	Citations
37	All Clinical Exomes Are Not Alike: Coverage Matters. Clinical Chemistry, 2020, 66, 9-11.	3.2	1
38	Abstract 11043: Lipoprotein(a) Cholesterol but not Lipoprotein (a) Mass is Significantly Correlated With Angiographic Coronary Artery Disease and Major Adverse Events. Circulation, 2015, 132, .	1.6	1
39	Classifying Germline Sequence Variants in the Era of Next-Generation Sequencing. Clinical Chemistry, 2016, 62, 799-806.	3.2	0
40	Direct-to-Consumer Genetic Testing in the Personalized Medicine Era. Point of Care, 2017, 16, 120-123.	0.4	0
41	Hypertrophic Cardiomyopathy in the General Population. Journal of the American College of Cardiology, 2021, 78, 1111-1113.	2.8	0
42	Warfarin pharmacogenetics: ready for clinical utility?. Clinical Laboratory Science: Journal of the American Society for Medical Technology, 2009, 22, 151-5.	0.1	0
43	Genetic markers for coronary artery disease. Clinical Laboratory Science: Journal of the American Society for Medical Technology, 2009, 22, 226-32.	0.1	0
44	Point of care CYP2C19 genotyping after percutaneous coronary intervention. Pharmacogenomics Journal, 2022, , .	2.0	0